Progress wrt commercialising Belluscura ’s (BELL ) best-of-breed portable oxygen concentrators (POC) is getting better by the day.
This morning, #BELL said that its flagship X-PLO2R device had achieved Centers for Medicare & Medicaid Services reimbursement coverage (re insurance) – addressing around 50% of the US POC market.
This is a major milestone, and should materially boost sales going forward.
CEO Bob Rauker commenting: "Receiving the two Medicare reimbursement codes should further expand access, alongside the use and distribution of the X-PLO2R throughout the US. We believe many Medicare patients will ask their health care providers and durable medical equipment providers to issue them with the lightweight X-PLO2R."
Belluscura 's next trading update is scheduled for early January 2022.